The authors conclude that they support the use of olanzapine, as evidence from three double blind trials, supported by evidence from a fourth which was of poorer quality, indicates that it is an effective and safe antipsychotic drug. However they note that although there is good evidence of excellent value for money, this is restricted to short term studies comparing olanzapine against older agents. Growth in the use of other new agents suggests the need for further comparative trials.